Impact of age and menopausal stage on serum anti-Müllerian hormone levels in middle-aged women

Zhang, J.; Wang, Xuefeng; Ren, Zhiguo; Shao, Shuang; Hou, Zhan; Wang, Z.; Xi, Jie; Bai, Wenpei

doi:10.1080/13697137.2021.1965114

Cited by 2 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this study included women with an established, rather than recent, menopause ( Shin et al , 2008 ), and therefore, the diagnostic accuracy may have been overestimated. However, in a further cross-sectional analysis of 288 healthy women aged 40–55 years, while AMH was progressively lower in women at later menopausal stages, age was found to have a greater impact on AMH levels than menopausal stage ( Zhang et al , 2021 ). No prospective studies undertaken in women prior to completion of 12 months of amenorrhoea to determine whether AMH could shorten the diagnostic timeframe of menopause, from the conventional 12 months of amenorrhoea, were identified.…”

Section: Resultsmentioning

confidence: 81%

“…Two cross-sectional studies and one longitudinal observational study assessed the age-related decline of AMH prior to the menopause ( Table I ). These studies included postmenopausal participants and demonstrated that undetectable AMH was strongly associated with menopausal stage ( de Vet et al , 2002 ; Shin et al , 2008 ; Zhang et al , 2021 ). In a study of 144 women, undetectable AMH had equivalent diagnostic accuracy to elevated FSH (where 22.3 mIU/ml was the optimal cut point) ( Shin et al , 2008 ).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review

Nelson

Davis

Kalantaridou

et al. 2023

Human Reproduction Update

View full text Add to dashboard Cite

BACKGROUND The early onset of menopause is associated with increased risks of cardiovascular disease and osteoporosis. As a woman’s circulating anti-Müllerian hormone (AMH) concentration reflects the number of follicles remaining in the ovary and declines towards the menopause, serum AMH may be of value in the early diagnosis and prediction of age at menopause. OBJECTIVE AND RATIONALE This systematic review was undertaken to determine whether there is evidence to support the use of AMH alone, or in conjunction with other markers, to diagnose menopause, to predict menopause, or to predict and/or diagnose premature ovarian insufficiency (POI). SEARCH METHODS A systematic literature search for publications reporting on AMH in relation to menopause or POI was conducted in PubMed®, Embase®, and the Cochrane Central Register of Controlled Trials up to 31 May 2022. Data were extracted and synthesized using the Synthesis Without Meta-analysis for diagnosis of menopause, prediction of menopause, prediction of menopause with a single/repeat measurement of AMH, validation of prediction models, short-term prediction in perimenopausal women, and diagnosis and prediction of POI. Risk-of-bias was evaluated using the Tool to Assess Risk of Bias in Cohort Studies protocol and studies at high risk of bias were excluded. OUTCOMES A total of 3207 studies were identified, and 41, including 28 858 women, were deemed relevant and included. Of the three studies that assessed AMH for the diagnosis of menopause, one showed that undetectable AMH had equivalent diagnostic accuracy to elevated FSH (>22.3 mIU/ml). No study assessed whether AMH could be used to shorten the 12 months of amenorrhoea required for a formal diagnosis of menopause. Studies assessing AMH with the onset of menopause (27 publications [n = 23 835 women]) generally indicated that lower age-specific AMH concentrations are associated with an earlier age at menopause. However, AMH alone could not be used to predict age at menopause with precision (with estimates and CIs ranging from 2 to 12 years for women aged <40 years). The predictive value of AMH increased with age, as the interval of prediction (time to menopause) shortened. There was evidence that undetectable, or extremely low AMH, may aid early diagnosis of POI in young women with a family history of POI, and women presenting with primary or secondary amenorrhoea (11 studies [n = 4537]). WIDER IMPLICATIONS The findings of this systematic review support the use of serum AMH to study the age of menopause in population studies. The increased sensitivity of current AMH assays provides improved accuracy for the prediction of imminent menopause, but diagnostic use for individual patients has not been rigorously examined. Prediction of age at menopause remains imprecise when it is not imminent, although the finding of very low AMH values in young women is both of clinical value in indicating an increased risk of developing POI and may facilitate timely diagnosis.

show abstract

Section: Resultsmentioning

confidence: 81%

Section: Resultsmentioning

confidence: 99%

Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review

Nelson

Davis

Kalantaridou

et al. 2023

Human Reproduction Update

View full text Add to dashboard Cite

show abstract

“…Ovarian functionality can be objectively assessed through three biomarkers: ovary volume, AMH, and AFC. The AMH serum concentration is a reliable predictor of ovarian aging approaching menopause (32,33) to evaluate a woman's fertility (17,18,20). A study analyzing the ovarian reserve (16) showed that combined HBC, as compared to progestin-only HBC, leads to a statistically significant decrease in AMH levels (−31.…”

Section: Ovarian Agingmentioning

confidence: 99%

Women's health, hormonal balance, and personal autonomy

2023

View full text Add to dashboard Cite

Hormone-based contraception disrupts hormonal balance, creating artificial states of anovulation and threatening women's health. We reviewed its main adverse effects and mechanisms on accelerated ovarian aging, mental health (emotional disruptions, depression, and suicide), sexuality (reduced libido), cardiovascular (brain stroke, myocardial infarction, hypertension, and thrombosis), and oncological (breast, cervical, and endometrial cancers). Other “collateral damage” includes negative effects on communication, scientific mistrust, poor physician–patient relationships, increased patient burden, economic drain on the healthcare system, and environmental pollution. Hormone-sensitive tumors present a dilemma owing to their potential dual effects: preventing some cancers vs. higher risk for others remains controversial, with denial or dismissal as non-relevant adverse effects, information avoidance, and modification of scientific criteria. This lack of clinical assessment poses challenges to women's health and their right to autonomy. Overcoming these challenges requires an anthropological integration of sexuality, as the focus on genital bodily union alone fails to encompass the intimate relational expression of individuals, complete sexual satisfaction, and the intertwined feelings of trust, safety, tenderness, and endorsement of women's femininity.

show abstract

Impact of age and menopausal stage on serum anti-Müllerian hormone levels in middle-aged women

Cited by 2 publications

References 32 publications

Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review

Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review

Women's health, hormonal balance, and personal autonomy

Contact Info

Product

Resources

About